Cargando…

Electrical neurostimulation in glaucoma with progressive vision loss

BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Erb, Carl, Eckert, Sophie, Gindorf, Pia, Köhler, Martin, Köhler, Thomas, Neuhann, Lukas, Neuhann, Thomas, Salzmann, Nadja, Schmickler, Stefanie, Ellrich, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969331/
https://www.ncbi.nlm.nih.gov/pubmed/35361287
http://dx.doi.org/10.1186/s42234-022-00089-9
_version_ 1784679224412471296
author Erb, Carl
Eckert, Sophie
Gindorf, Pia
Köhler, Martin
Köhler, Thomas
Neuhann, Lukas
Neuhann, Thomas
Salzmann, Nadja
Schmickler, Stefanie
Ellrich, Jens
author_facet Erb, Carl
Eckert, Sophie
Gindorf, Pia
Köhler, Martin
Köhler, Thomas
Neuhann, Lukas
Neuhann, Thomas
Salzmann, Nadja
Schmickler, Stefanie
Ellrich, Jens
author_sort Erb, Carl
collection PubMed
description BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered. RESULTS: Perimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB. CONCLUSIONS: Innovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials.
format Online
Article
Text
id pubmed-8969331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89693312022-04-01 Electrical neurostimulation in glaucoma with progressive vision loss Erb, Carl Eckert, Sophie Gindorf, Pia Köhler, Martin Köhler, Thomas Neuhann, Lukas Neuhann, Thomas Salzmann, Nadja Schmickler, Stefanie Ellrich, Jens Bioelectron Med Research Article BACKGROUND: The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. METHODS: Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered. RESULTS: Perimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB. CONCLUSIONS: Innovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials. BioMed Central 2022-03-31 /pmc/articles/PMC8969331/ /pubmed/35361287 http://dx.doi.org/10.1186/s42234-022-00089-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Erb, Carl
Eckert, Sophie
Gindorf, Pia
Köhler, Martin
Köhler, Thomas
Neuhann, Lukas
Neuhann, Thomas
Salzmann, Nadja
Schmickler, Stefanie
Ellrich, Jens
Electrical neurostimulation in glaucoma with progressive vision loss
title Electrical neurostimulation in glaucoma with progressive vision loss
title_full Electrical neurostimulation in glaucoma with progressive vision loss
title_fullStr Electrical neurostimulation in glaucoma with progressive vision loss
title_full_unstemmed Electrical neurostimulation in glaucoma with progressive vision loss
title_short Electrical neurostimulation in glaucoma with progressive vision loss
title_sort electrical neurostimulation in glaucoma with progressive vision loss
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969331/
https://www.ncbi.nlm.nih.gov/pubmed/35361287
http://dx.doi.org/10.1186/s42234-022-00089-9
work_keys_str_mv AT erbcarl electricalneurostimulationinglaucomawithprogressivevisionloss
AT eckertsophie electricalneurostimulationinglaucomawithprogressivevisionloss
AT gindorfpia electricalneurostimulationinglaucomawithprogressivevisionloss
AT kohlermartin electricalneurostimulationinglaucomawithprogressivevisionloss
AT kohlerthomas electricalneurostimulationinglaucomawithprogressivevisionloss
AT neuhannlukas electricalneurostimulationinglaucomawithprogressivevisionloss
AT neuhannthomas electricalneurostimulationinglaucomawithprogressivevisionloss
AT salzmannnadja electricalneurostimulationinglaucomawithprogressivevisionloss
AT schmicklerstefanie electricalneurostimulationinglaucomawithprogressivevisionloss
AT ellrichjens electricalneurostimulationinglaucomawithprogressivevisionloss